2843 E. Grand River Avenue – #230 East Lansing, MI 48823 annie@nlmsf.org 303-783-0924

Whats New in Leiomyosarcoma Research?


Leiomyosarcoma Research Articles and News- Updates:

Image result for research

July 25, 2017:

June 18, 2017:

  • Johns Hopkins researchers say they’ve unlocked key to cancer metastasis and how to slow it: http://www.baltimoresun.com/health/bs-hs-cancer-trigger-20170625-story.html

June 29, 2017:

  • Phase 3 results trabectedin or dacarbazine in ULMS-

    Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

    Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study.


June 28, 2017:

June 10, 2017:
Mechanism of action and tolerability of trabectedin for liposarcoma and leiomyosarcoma

  • http://www.researchtopractice.com/STSU117/Video/3

June 9, 2017:

  • ASCO 2017 Sarcoma/LMS Related Research Presentations
    The meeting slides through the ASCO Meeting Library

June 6, 2017:

May 31, 2017:

May 27, 2017:


May 24, 2017:

  • Here is an interesting article to discuss with your oncologist.Some of the medical terminology definitions are provided to help you with the information provided in the article.

    Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma

    Link: https://www.ncbi.nlm.nih.gov/pubmed/28386017

    Definitions:  Rapalog: Analogs of rapamycin (MTOR inhibitor) Immunosupressant/ anti-cancer properties of rapamycin
    Glycosis –  the enzymatic breakdown of clucose or other carbohydrate by wan of phosphate derivatives
    Phenotypic –  detectable expression of the genotype and environment constituting visible characteristics . .  .
    Let me know if you need more information to better understand this article and I will try to help you.



May 19, 2017:

May 3, 2017:

May 2, 2017:

April 1, 2017:

April 25, 2017:

April 20, 2017:

  • Further clarification of the “rare cancer cell line project” announced on a previous E-Bulletin.The cancer cell line project is a collaborative effort of the Broad Institute of MIT/Harvard and the Rare Cancer Research Foundation, a non-for profit foundation.  This project was created because both parties felt that there were not enough “living” cancer cell lines of rare cancer in existence and the lack of sufficient cell line was hindering the advancement of research on these rare tumors. The Project does receive some funding from the NIHA little more background information would be helpful.  The Broad Institute of MIT and Harvard was launched in 2004 to improve human health by using genomics to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies.  If you wish you can learn more about the Broad Institute of MIT and Harvard on their official website https://www.broadinstitute.org.  More information about the Rare Cancer Research Foundation can be obtained on their website.The Cancer Cell line Project is not a new project.  However, inclusion of Leiomyosarcoma into the small group (8 previous rare cancers in the project) is NEW.  The Cancer Cell line Project was looking to add a few more rare cancers to those already in the project.  The NLMSF working with the RCRF was able to get LMS accepted as one of the new rare cancers in the project.  Our application had to be accepted by both the RCRF and the Broad Institute.The Cancer Cell Line Project is under the purview of the Institutional Review Board (IRB) of the Broad institute.  In accordance with FDA regulations, and IRB which is an independent entity, had the authority to approve, require modifications in (to secure approval) or disapprove research.  This group review serves an important role in the protection of the rights and welfare of human research subjects.  The IRB provides ongoing oversight of the research to ensure compliance.The Cancer Cell Line Project is not in the in a strict definition a specific research project.  Its goal to develop “living” rare cancer lines (tissue cell cultures) that they can then genomically characterize and then share with other researchers throughout the world for use in their research endeavors.  Those researchers if they have the means to do so can also continue to “grow” the tumor cell lines in their labs for future research.  A created tumor cell line is truly remarkable thing.  The gift to patients that keeps on giving.As most of you probably already know, there is an LMS Tissue Bank at Dr. Matt Van de Rijn’s lab at Stanford.  This is one of if not the largest collections of  LMS patient tumor samples in the world.  It is a tremendous resource for LMS researchers.  The NLMSF strongly supports this tissue bank and encourages all LMS patients to have paraffin block samples of their tumors sent to this tissue bank for use in current and future research projects.  Our foundation has helped to fund research in Dr. van de Rijn’s lab for many years and he recently graciously accept to become a member of the Medical Advisory Committee of our Foundation.The Broad Institute Cell Line Project does not conflict or compete with the LMS Tissue Bank at Stanford.  These are complementary projects that in different ways will help to advance LMS research.  The Cancer Cell Lines developed at the Broad Institute require fresh tumor tissue samples for their creation.  Living cancer cell lines cannot be created from tissue stored in paraffin block.  That is why tumor cell line creation  is not only difficult and costly,  but also requires coordination at many levels.  That is why so few tumor cell lines exist.The beauty of the collaborative project of the RCRF and the Broad Institute is that do to funding that they have been able to attain they have made the acquisition of a sample fresh of a patient’s tumor tissue obtained at the time of surgery or biopsy at any hospital in the United States as easy as possible.
    Other than giving consent to donate a small portion of their tumor tissue sample,  a portion not needed for their treatment, the process proceeds without any involvement or effort by the patient.  The patient’s tumor tissue sample is de-identified before it is sent to the Broad Institute.  The researchers creating the tumor cell line will know no personal information about the patient who donated the tissue.  The patient will not receive any information back about their tumor or any future research done on their tumor.The choice to donate a sample of their tumor tissue to the Cancer Cell Line Project is solely and completely up to the patient.  It is an on-line process.  The NLMSF’s involvement is only to inform you that the project exists.  We will have no knowledge of who chooses to participate.  The NLMSF will receive no financial gain or other compensation from the RCRF  or the Broad institute.
    April 11, 2017:

    April 9, 2017:

    • The National Leiomyosarcoma Foundation announces an exciting new collaborative partnership with the Rare Cancer Research Foundation (RCRF), which will allow Leiomyosarcoma (LMS) patients to DIRECTLY DONATE their FRESH TUMOR TISSUE to be used for the creation of new LMS TUMOR CELL LINES, which can be used for future LMS research by researchers throughout the world.The RCRF has created a program with the Broad Institute of MIT and Harvard dedicated to the creation of new tumor cell lines of rare cancers called  The Cancer Cell Line Project”. Only a limited number of rare cancers are and will be included in this project. Cell Lines mean:  tumor tissue in vitro (Petri dish) for analysis and testing to continue to grow more tumor tissue/cells for further research study initiatives. For more information: http://eepurl.com/cKoS0z

    April 4, 2017:

    March 7, 2017:

    • Community Healthcare Systems Seeking To Incorporate Genetic Testing Into Cancer Care They Offer:
      The Wall Street Journal (3/6, Kincaid, Subscription Publication, 6.37M) reports community healthcare systems are seeking to incorporate genetic testing into the cancer care they provide. Richard Schilsky, chief medical officer of the American Society of Clinical Oncology, points out that most patients with cancer receive care in a community setting, though testing tumors for multiple genetic mutations has been more prevalent in academic settings where oncologists have the resources to interpret complicated results.

    February 20, 2017:

    • Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial-The expression level of specific microRNAs in soft tissue sarcoma tissue samples might predict response to eribulin. Click here for the full study

    February 7, 2017:

    February 3, 2017: 

    January 31, 2017:

    January 19, 2017:

    December 12, 2016:

    December 3, 2016: 

    October 24, 2016:

    October 19th, 2016:

    October 14, 2016:

    • Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomized, double-blind, placebo-controlled, phase 2 trial. Patients and Families- Click the Link “The Lancet Oncology”   to read the rest of the article.  This is important information to discuss with your oncologist /oncology medical team. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30507-1/abstract

    October 10, 2016:

    • Neoadjuvant anthracycline plus ifosfamide chemotherapy was linked to significantly increased survival rates in patients with soft tissue sarcomas located in the torso or extremities who were at high risk of recurrence. Click here for more information.
    • Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Click here for the abstract.

    October 07, 2016:

    • Trabectedin Improves PFS vs Best Supportive Care in Sarcoma

      Trabectedin significantly improves progression-free survival in patients with pretreated advanced soft tissue sarcomas.

      Click here for more information.

    October 1, 2016:

    • High expression of proteasome activator complex subunit 1 (PSME1) is associated with poor survival in soft tissue leiomyosarcoma patients and might be used to predict the likely course of the disease.
    Definitions of a few of the terms in order of their appearance in this article:
    Spectrometry –  a measuring instrument for the study of the interaction of matter involving molecules or other material related to the study (and involving wavelength or frequency).
    Proteasome –  cellular protein – damaged/degraded
    immunoproteasome –  a proteasome assembled in response to pro-inflammatory signals.
    Microarrays – molecules (or fragments), usually of DNA or protein, attached in a pattern for use in biochemical or genetic analysis.
    Covariates –   known, controlled variables that may affect the outcome of a clinical trial.
    Immunohistochemistry –  demonstration of specific antigens (harmful antibodies) in tissues by the use of dyes or fluorescent markers.
    Histological –  study of microscopic tissue structures
    Biomarker –  a distinctive biological indicator of a disease process –  biochemical, genetic, or molecular characteristic.

    Click here for more information on the study.

    September 2016:

    • The BMC ( British Journal of Cancer) features an article on molecular classification of uterine leiomyosarcomas. Their data supports the existence of distinct leiomyosarcoma subgroups which are clinically associated with tumor grades. These findings will help advance the classification of leiomyosarcomas and promote more individualized treatments. Click here for the abstract.

    August 8, 2016:

    • The Liddy Shriver Sarcoma Initiative is funding a $1 million international collaborative grant for leiomyosarcoma (LMS) research. The two-year project will enlist investigators from France, Germany, and the United States with the aim of identifying new therapies and starting clinical trials for the most prevalent and clinically challenging types of LMS.
    • The Grant Announcement  – “$1 Million Study on Leiomyosarcoma Set to Begin” –http://bit.ly/2bcT1iq

      The Experimental Plan Article – Maximizing Therapeutic Response in Leiomyosarcoma –http://bit.ly/2aSLxR2

    For more information, visit the website http://sarcomahelp.org/leiomyosarcoma-collaborative-research.html
    July 2016:

    • A study exploring chromosomal abnormalities in uterine smooth muscle tumors found that uterine leiomyomas with abnormal nuclei and leiomyosarcomas are closely related. Click here for the abstract.

May 2016:

  • A study published by the BJC found that antiapoptotic (anti-cell death) Bc1-2 family proteins are highly expressed in soft tissue leiomyosarcomas and inhibition of these proteins increases tumor sensitivity to chemotherapy. Click here for the abstract.

January 2016: